Kitazato

Kitazato Financing Cash Flow

The Net Financing Cash Flow of Kitazato (368A.T) as of Nov 17, 2026 is -1.66 B JPY. In the previous year, Net Financing Cash Flow was -2.07 B JPY — a change of -19.98% (higher).

Financing Cash Flow

-1.66 BJPY

YoY

-19.98%

Last updated:

Net Financing Cash Flow of Kitazato is 2025 -1.66 B JPY. Net Financing Cash Flow of Kitazato was 2024 -2.07 B JPY. It decreases by -19.98% higher compared to the previous year.

The Kitazato Financing Cash Flow history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Financing Cash Flow
Date
Financing Cash Flow
Jan 1, 2023
-1.27 B JPY
Jan 1, 2024
-2.07 B JPY
Jan 1, 2025
-1.66 B JPY
The Kitazato Financing Cash Flow history
YEARFinancing Cash FlowYoY
-1.66 BJPY-19.98%
-2.07 BJPY+63.15%
-1.27 BJPY—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Kitazato Stock analysis

What does Kitazato do? Kitazato Corp manufactures and sells medical devices, reagents, and related products for infertility treatment, specializing in reproductive engineering technology for artificial insemination, in vitro fertilization, and cell cryopreservation. The company produces consumables such as medical equipment and reagents used in in vitro fertilization and intracytoplasmic sperm injection, including media, cryo devices, medical devices, and micro tools. Kitazato Corp distributes its products globally, serving markets in Japan, Europe, the United States, China, and India, with a focus on research reagents and medical equipment for infertility treatment. The firm also manufactures and sells medical equipment parts, provides genetic testing services, and offers medical equipment for the elderly. Additionally, Kitazato Corp engages in market research, acquisition of local licenses, and contract management of living cells, expanding its reach into regenerative medicine and related fields. These services and products target healthcare providers, fertility clinics, and research institutions worldwide. Kitazato Corp's revenue streams include the sale of consumables, medical devices, and reagents, as well as genetic testing and contract management services. The company's global distribution network supports sales across key regions, with a strong emphasis on infertility treatment solutions and regenerative medicine technologies. Kitazato is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Kitazato stock

Net Financing Cash Flow of Kitazato is -1.66 B JPY in 2025.

Net Financing Cash Flow of Kitazato changed from -2.07 B JPY to -1.66 B JPY, representing a -19.98% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of Net Financing Cash Flow Kitazato since 2006 – with annual values, charts, and detailed analysis.

Financing cash flow measures cash flows from debt issuance/repayment, equity transactions, and dividend payments.

Net Financing Cash Flow's JPY is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track Net Financing Cash Flow's Kitazato historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Cash Flow — Kitazato

All Key Metrics — Kitazato